SGC & HitGen Sign Research collaboration For Drug Discovery

HitGen Inc. established a collaboration with The Structural Genomics Consortium (SGC), a public-private partnership dedicated to the development of novel therapeutics through open-access research. HitGen will evaluate under-represented targets identified by SGC using their DNA-encoded library (DEL) technology platform, especially OpenDEL. The screening datasets will be posted to a publicly accessible portal to facilitate drug discovery, and ML experts from around the world will model the data and make predictions about new active molecules that will be experimentally tested at SGC as part of the Target 2035 initiative.

HitGen is a world leader in DEL technology development and applications to early-stage small molecule drug discovery. Its platform has approximately 1.2 trillion small molecules created using DEL technology, and the effectiveness of the screening process has enabled HitGen to facilitate drug development initiatives for numerous organizations worldwide.

OpenDEL is a self-service DEL kit with over 3 billion compounds, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support, as per pharmabiz.